期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 28, 期 6, 页码 1023-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2014.08.003
关键词
Myeloproliferative neoplasms (MPN); Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Hematopoietic stem cell transplantation; Ruxolitinib
资金
- National Institutes of Health [HL036444]
Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders. While some MPN patients have an indolent course, all are at risk of progressing to severe marrow failure or transforming into acute leukemia. Allogeneic hematopoietic cell transplantation (allo-HCT) is the only potential curative therapy. Major pre-transplant risk factors are disease stage of the MPN, the presence of comorbid conditions and the use of HLA non-identical donors. The development of reduced-intensity conditioning regimens has allowed for successful allo-HCT even for older patients and patients with comorbid conditions. The pre-transplant use of JAK2 inhibitors, which may be effective in down staging a patient's disease, may improve the outcomes following allo-HCT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据